Article Text

Download PDFPDF
Snippets in haematology
  1. Scott McCloskey,
  2. Mary Frances McMullin
  1. Department of Haematology, Belfast City Hospital, Belfast, UK

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

British Journal of Haematology

July 2010

Berenson JR, Anderson KC, Audell RA, et al. Monoclonal gammopathy of undetermined significance: a consensus statement. Br J Haematol 2010;150:28–38.

Paraproteins are common in the elderly population and less than 1% per year will transform to a more serious B cell malignancy. In light of the low transformation rate, afflicted patients do not need to be referred to a haematologist. Rather, this guideline provides advice on the diagnosis, staging and follow-up of monoclonal gammopathy of undetermined significance, and raises awareness of the associated problems of peripheral neuropathy, thromboembolic disease and osteoporosis.

Coiffier B, Losic N, Ronn BB, et al. Pharmacokinetics and pharmacokinetic/pharmacodynamic associations of ofatumumab, a human monoclonal CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukaemia: a phase 1–2 study. Br J Haematol 2010;150:58–71.

Rituximab is a monoclonal antibody to the CD20 transmembrane protein, and it has significantly improved outcomes in many B cell lymphoproliferative disorders. Ofatumumab is a new anti-CD20 monoclonal antibody that induces apoptosis through complement activation and antibody-dependent cell-mediated cytotoxicity. Ofatumumab can induce responses in rituximab-resistant patients. In this phase 2 trial of 37 patients with CLL, efficacy was inversely proportional to body size and clearance. Ofatumumab was detectable in the serum 7 months after the last high-dose infusion.

Greenberg PL. Current therapeutic approaches for patients with myelodysplastic syndromes. Br J Haematol 2010;150:131–43.

Myelodysplasia and leukaemia are at opposite ends of a spectrum of haematopoietic dysfunction affecting proliferation and differentiation. Myelodysplasia can be stratified into high risk and low risk depending on the blast percentage, cytogenetic abnormalities and number of cytopenias. Management ranges from observation to intensive chemotherapies. The indications for lenalidomide, granulocyte colony-stimulating factor and erythropoietin and their outcomes in low risk patients are discussed. Immunosuppressive therapy is recommended in younger patients with …

View Full Text


  • Provenance and peer review Not commissioned; internally peer reviewed.